Familial Hypercholesterolemia Market

The total diagnosed prevalent population of Familial Hypercholesterolemia (FH) in the 7MM was 965,405 in 2017, which is anticipated to increase by 2030. Also, the diagnosed prevalent population of FH was found to be 244,214 in the United States during the same period.

The market size of Familial Hypercholesterolemia in the 7MM was found to be USD 1,069.27 Million in 2017.

Emerging therapies and promising organizations are some of the key factors expected to drive the FH market in the coming years, while late diagnosis, differential diagnosis, lack of Homozygous FH (HoFH) are major barriers in the advancement of the Familial Hypercholesterolemia market.

The key players in the Familial Hypercholesterolemia market includes Regeneron Pharmaceuticals, Novartis, Arrowhead Pharmaceuticals, NeuroBo Pharmaceuticals, Madrigal Pharmaceuticals, and others.

For more information visit: https://www.delveinsight.com/report-store/familial-hypercholesterolemia-type-ii-hyperlipoproteinemia-market